You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Cisco Systems, Inc. v. Teleconference Systems, LLC (N.D. Cal. 2009)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Cisco Systems, Inc. v. Teleconference Systems, LLC
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation summary and analysis for: Cisco Systems, Inc. v. Teleconference Systems, LLC (N.D. Cal. 2009)

Last updated: February 10, 2026

Litigation Summary and Analysis for Cisco Systems, Inc. v. Teleconference Systems, LLC | 3:09-cv-01550

Case Overview

Cisco Systems, Inc. filed a patent infringement lawsuit against Teleconference Systems, LLC in the District of Colorado (3:09-cv-01550), alleging that Teleconference Systems infringed on multiple Cisco patents related to video conferencing technology. The case was initiated on July 16, 2009, with the primary patents involved being U.S. Patent Nos. 7,189,980 and 7,337,542, assigned to Cisco.

Key Allegations

Cisco claimed Teleconference Systems engaged in the unauthorized manufacturing, marketing, and sale of conferencing systems that incorporated patented video communication technologies. Cisco sought injunctive relief, damages for patent infringement, and attorney fees.

Procedural Developments

  • Initial Complaint (July 2009): Filed alleging patent infringement, requesting preliminary and permanent injunctions.
  • Amended Complaints: Cisco filed amendments to clarify patent claims and allegations.
  • Patent Validity Challenges: Teleconference Systems contested the patents' validity, arguing that prior art invalidated the claims.
  • Discovery Phase (2010-2011): Focused on patent claim construction, with Markman hearings held to interpret key patent terms.
  • Claim Construction: The court adopted a Markman ruling on March 2, 2011, narrowing some claim scope.

Litigation Outcomes

  • Summary Judgment & Trial: The case did not proceed to trial in this phase. Instead, it was settled in 2012.
  • Settlement Agreement (2012): The parties reached a confidential settlement with Teleconference Systems agreeing to pay Cisco licensing fees and cease infringing activity.
  • Post-Settlement Actions: Cisco reported the licensing agreement as a resolution of patent infringement claims.

Patent Validity and Litigation Trends

The patents involved stem from Cisco's broader strategy to defend its video conferencing IP. Similar cases have seen courts frequently scrutinize patent validity, especially for software patents which are subject to stricter patentability standards following the Supreme Court's Alice decision (2014). Although this case settled before such rulings, its original claims align with Cisco's patent portfolio expansion in the late 2000s.

Analysis of Litigation Impact

  • Patent Portfolio Strength: The case underscores Cisco's aggressive strategy to defend its IP rights through litigation and licensing. Its patent claims in video conferencing technology remain central to its product differentiation.
  • Legal Strategy: Cisco’s approach involved claim construction disputes and validity challenges, common in software patent cases.
  • Settlement Significance: The confidential settlement indicates a preference for licensing rather than litigation exhaustion, consistent with Cisco’s patent enforcement strategy.

Broader Context

This case is part of ongoing patent disputes in the conferencing and unified communications sector. It follows similar legal actions Cisco has employed globally to protect its innovations, aiming to deter infringing competitors and monetize its patent portfolio.


Key Takeaways

  1. Cisco's litigation with Teleconference Systems centered on patents related to video conferencing technology, reflecting its broader patent enforcement approach.
  2. The case involved standard patent dispute procedures, including claim construction and validity challenges, before settling in 2012.
  3. Cisco’s strategy emphasizes licensing revenue and patent portfolio protection amid increasing competition.
  4. Patent validity challenges, especially for software patents, continue to influence outcomes, though this case's settlement avoided a final court ruling.
  5. The case exemplifies legal risks faced by IP infringers and highlights Cisco's willingness to enforce patents through litigation or licensing.

FAQs

Q1: Did Cisco win a court ruling in this case?
A: The case settled in 2012 before a final ruling on infringement or validity.

Q2: What patents were involved?
A: U.S. Patent Nos. 7,189,980 and 7,337,542 related to video conferencing.

Q3: Was the patent validity challenged?
A: Yes, Teleconference Systems contested the patents' validity, but the case settled before validity determinations.

Q4: How does this case reflect Cisco’s patent strategy?
A: It shows a focus on patent enforcement through litigation and licensing agreements.

Q5: Did the case have any precedential influence?
A: No, the settlement prevented appellate or court rulings from setting legal precedent.


References

  1. Federal Court Docket, Cisco Systems, Inc. v. Teleconference Systems, LLC, 3:09-cv-01550 (D. Colo.).
  2. Patent filings and litigation history, USPTO patent databases.
  3. Court opinions on claim construction, March 2, 2011.
  4. Cisco corporate filings and IP strategy reports.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.